The debate surrounding cancer endpoints has focused on the issue of quality of life and progression. Panelists shared some of the challenges in assessing quality of life, since it can be a fickle and subjective process. The data can be hard to nail down since patients don’t always fill out the forms. The critical issues include survival rates, improved quality of life and progression of disease. Everything must be taken into consideration to determine endpoints, which is why the issue is hotly debated.
Subscribe to our e-newsletterVIEW OUR CURRENT ISSUE >
Tags2016 BIO International Convention patents BIO EVENT BIO President and CEO Jim Greenwood BIOTECH Health Care Benefits of biotech crops healthcare USPTO BIO International Convention highlights GMOs GMO Answers Plant biotechnology Events vaccines USDA GMO agriculture health
- Most Popular